A new look at the 5α-reductase inhibitor finasteride

CNS Drug Reviews

Volumn 12, Issue 1, 2006, Pages 53-76

  Finn, Deborah A ^a,b   Beadles Bohling, Amy S ^a   Beckley, Ethan H ^a   Ford, Matthew M ^a   Gililland, Katherine R ^a   Gorin Meyer, Rebecca E ^a   Wiren, Kristine M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Alcohol withdrawal; Allopregnanolone; Depression; Epilepsy; Finasteride; Neuroactive steroids; Seizure susceptibility; Sexual behavior

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; ANDROSTANOLONE; DEOXYCORTICOSTERONE; FINASTERIDE; PROGESTERONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR;

ALCOHOL WITHDRAWAL; ANTICONVULSANT ACTIVITY; BRAIN FUNCTION; CATAMENIAL EPILEPSY; DEPRESSION; DRUG ACTIVITY; DRUG INHIBITION; HUMAN; MALE TYPE ALOPECIA; NEUROTRANSMISSION; NONHUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PROSTATE HYPERTROPHY; REVIEW; TRANQUILIZING ACTIVITY; ALCOHOLISM; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; SEIZURE; SEXUAL BEHAVIOR;

ALCOHOL-RELATED DISORDERS; CHOLESTENONE 5 ALPHA-REDUCTASE; DEPRESSION; ENZYME INHIBITORS; FINASTERIDE; MODELS, BIOLOGICAL; SEIZURES; SEXUAL BEHAVIOR;

EID: 33746563657     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00053.x     Document Type: Review

References (156)

1. Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002;29:665-669.
2. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5α-reductase 2 gene in male pseudo-hermaphroditism. Nature 1991;354:159-161.
3. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 1990;87:3640-3644.
4. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004;172:1399-1403.
5. Azzolina B, Ellsworth K, Andersson S, Geissler W, Bull HG, Harris GS. Inhibition of rat α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition. J Steroid Biochem Mol Biol 1997;61:55-64.
6. Barbaccia ML, Affricano D, Trabucchi M, et al. Ethanol markedly increases "GABAergic" neurosteroids in alcohol-preferring rats. Eur J Pharmacol 1999;384:R1-2.
7. Bayram F, Muderris I, Guven M, Ozcelik B, Kelestimur F. Low-dose (2.5 mg/day) finasteride treatment in hirsutism. Gynecol Endocrinol 2003;17:419-422.
8. A receptor. Nat Rev Neurosci 2005;6:565-575.
9. Bergeson SE, Warren RK, Crabbe JC, Metten P, Erwin VG, Belknap JK. Chromosomal loci influencing chronic alcohol withdrawal severity. Mamm Genome 2003;14:454-463.
10. Birzniece V, Backstrom T, Johansson IM, et al. Neuroactive steroid effects on cognitive functions with a focus on the serotonin and GABA systems. Brain Res Brain Res Rev 2005[epub, ahead of print].
11. Bitran D, Dugan M, Renda P, Ellis R, Foley M. Anxiolytic effects of the neuroactive steroid pregnanolone (3α-OH-5 β-pregnan-20-one) after microinjection in the dorsal hippocampus and lateral septum. Brain Res 1999;850:217-224.
12. A receptors. J Neuroendocrinol 1995;7:171-177.
13. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 1995;52:113-133.
14. A receptors. Eur J Pharmacol 1997;325:1-7.
15. Brunet M, Rodamilans M, Martinez-Osaba MJ, et al. Effects of long-term antiepileptic therapy on the catabolism of testosterone. Pharmacol Toxicol 1995;76:371-375.
16. A receptors. Mol Pharmacol 2003;63:53-64.
17. Cagetti E, Pinna G, Guidotti A, Baicy K, Olsen RW. Chronic intermittent ethanol (CIE) administration in rats decreases levels of neurosteroids in hippocampus, accompanied by altered behavioral responses to neurosteroids and memory function. Neuropharmacology 2004;46:570-579.
18. 14C]finasteride after oral administration in humans. Drug Metab Dispos 1992;20:148-155.
19. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf) 2002;57:231-234.
20. Celotti F, Negri-Cesi P, Poletti A. Steroid metabolism in the mammalian brain: 5α-Reduction and aromatization. Brain Res Bull 1997;44:365-75.
21. Cilotti A, Danza G, Serio M. Clinical application of 5α-reductase inhibitors. J Endocrinol Invest 2001;24:199-203.
22. Ciotta L, Cianci A, Calogero AE, et al. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil Steril 1995;64:299-306.
23. 1-blockers for benign prostatic hyperplasia? A nested case-control study. Pharmacoepidemiol Drug Safety 2002;11:55-61.
24. Concas A, Mostallino MC, Porcu P, et al. Role of brain allopregnanolone in the plasticity of γ-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc Natl Acad Sci USA 1998;95:13284-13289.
25. Crabbe JC. Provisional mapping of quantitative trait loci for chronic ethanol withdrawal severity in BXD recombinant inbred mice. J Pharmacol Exp Ther 1998;286:263-271.
26. Crabbe JC, Jr., Young ER, Kosobud A. Genetic correlations with ethanol withdrawal severity. Pharmacol Biochem Behav 1983;18(Suppl 1):541-547.
27. Criswell HE, Breese GR. A conceptualization of integrated actions of ethanol contributing to its GABAmimetic profile: A commentary. Neuropsychopharmacology 2005;30:1407-1425.
28. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703-706.
29. Dazzi L, Serra M, Seu E, et al. Progesterone enhances ethanol-induced modulation of mesocortical dopamine neurons: Antagonism by finasteride. J Neurochem 2002;83:1103-1109.
30. Edinger KL, Frye CA. Testosterone's analgesic, anxiolytic, and cognitive-enhancing effects may be due in part to actions of its 5α-reduced metabolites in the hippocampus. Behav Neurosci 2004;118:1352-1364.
31. Ellis JA, Panagiotopoulos S, Akdeniz A, Jerums G, Harrap SB. Androgenic correlates of genetic variation in the gene encoding 5α-reductase type 1. J Hum Genet 2005;50:534-537.
32. Feder HH. Hormones and sexual behavior. Annu Rev Psychol 1984;35:165-200.
33. Finn DA, Beadles-Bohling AS, Tanchuck MA, Gililland KR, Mark GP. The hippocampus is an important brain site necessary for the anticonvulsant effect of allopregnanolone in WSP-I mice. Alcohol Clin Exp Res 2005;29:95A.
34. Finn DA, Ford MM, Wiren KM, Roselli CE, Crabbe JC. The role of pregnane neurosteroids in ethanol withdrawal: Behavioral genetic approaches. Pharmacol Ther 2004;101:91-112.
35. Finn DA, Long SL, Tanchuck MA, Crabbe JC. Interaction of chronic ethanol exposure and finasteride: Sex and strain differences. Pharmacol Biochem Behav 2004;78:435-443.
36. Finn DA, Sinnott RS, Ford MM, Long SL, Tanchuck MA, Phillips TJ. Sex differences in the effect of ethanol injection and consumption on brain allopregnanolone levels in C57BL/6 mice. Neuroscience 2004;123:813-819.
37. A receptor gene expression by allopregnanolone and ethanol. Eur J Pharmacol 2004;500:413-425.
38. Ford MM, Nickel JD, Finn DA. Treatment with and withdrawal from finasteride alter ethanol intake patterns in male C57BL/6J mice: Potential role of endogenous neurosteroids? Alcohol 2005;37:23-33.
39. Freeman EW, Frye CA, Rickels K, Martin PA, Smith SS. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 2002;22:516-520.
40. Frye CA. The role of neurosteroids and nongenomic effects of progestins in the ventral tegmental area in mediating sexual receptivity of rodents. Horm Behav 2001;40:226-233.
41. Frye CA, Bayon LE. Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3α,5α-THP. Neuroendocrinology 1998;68:272-280.
42. Frye CA, Bayon LE, Pursnani NK, Purdy RH. The neurosteroids, progesterone and 3α,5α-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res 1998;808:72-83.
43. Frye CA, Murphy RE, Platek SM. Anti-sense oligonucleotides, for progestin receptors in the VMH and glutamic acid decarboxylase in the VTA, attenuate progesterone-induced lordosis in hamsters and rats. Behav Brain Res 2000;115:55-64.
44. Frye CA, Reed TA. Androgenic neurosteroids: Anti-seizure effects in an animal model of epilepsy. Psychoneuroendocrinology 1998;23:385-399.
45. Frye CA, Rhodes ME. Progesterone's 5α-reduced metabolite, 3α,5α-THP, mediates lateral displacement of hamsters. Brain Res 2005;1038:59-68.
46. Frye CA, Scalise TJ, Bayon LE. Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J Neuroendocrinol 1998;10:291-296.
47. A receptor activity. J Neuroendocrinol 1999;11:829-837.
48. Frye CA, Vongher JM. Progesterone and 3α,5α-THP enhance sexual receptivity in mice. Behav Neurosci 2001;115:1118-1128.
49. Frye CA, Vongher JM. Ventral tegmental area infusions of inhibitors of the biosynthesis and metabolism of 3α,5α-THP attenuate lordosis of hormone-primed and behavioural oestrous rats and hamsters. J Neuroendocrinol 2001;13:1076-1086.
50. Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav 2002;41:306-315.
51. Frye CA, Walf AA. Hippocampal 3α,5α-THP may alter depressive behavior of pregnant and lactating rats. Pharmacol Biochem Behav 2004;78:531-540.
52. Gabriel KI, Cunningham CL, Finn DA. Allopregnanolone does not influence ethanol-induced conditioned place preference in DBA/2J mice. Psychopharmacology (Berl) 2004;176:50-56.
53. Gasior M, Carter RB, Witkin JM. Neuroactive steroids: Potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol Sci 1999;20:107-112.
54. A receptor complex: The pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 1995;9:207-227.
55. Geller J. Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 1990;71:1552-1555.
56. Gilman DP, Hitt JC. Effects of gonadal hormones on pacing of sexual contacts by female rats. Behav Biol 1978;24:77-87.
57. Girman CJ, Kolman C, Liss CL, Bolognese JA, Binkowitz BS, Stoner E. Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group. Prostate 1996;29:83-90.
58. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors G1198745 and finasteride. Clin Pharmacol Ther 1998;64:636-647.
59. Gorin-Meyer RE, Wiren KM, Tanchuck MA, Long SL, Finn DA. Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6J and DBA/2J mice. submitted.
60. Gorin RE, Crabbe JC, Tanchuck MA, Long SL, Finn DA. Effects of finasteride on chronic and acute ethanol withdrawal severity in the WSP and WSR selected lines. Alcohol Clin Exp Res 2005;29:939-948.
61. Gormley GJ. Finasteride: A clinical review. Biomed Pharmacother 1995;49:319-24.
62. Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990;70:1136-1141.
63. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999;96:13512-13517.
64. A receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 1998;139:2-19.
65. 3]finasteride and quantitative determination of finasteride in human plasma at picogram level by an isotope-dilution mass spectrometric method. J Chromatogr B Biomed Appl 1995;674:197-204.
66. Guarna A, Occhiato EG, Danza G, Conti A, Serio M. 5α-reductase inhibitors, chemical and clinical models. Steroids 1998;63:355-361.
67. Harrison NL, Simmonds MA. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res 1984;323:287-292.
68. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003;53:390-391.
69. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-1088.
70. Hill M, Popov P, Havlikova H, et al. Altered profiles of serum neuroactive steroids in premenopausal women treated for alcohol addiction. Steroids 2005;70:515-524.
71. Hill M, Popov P, Havlikova H, et al. Reinstatement of serum pregnanolone isomers and progesterone during alcohol detoxification therapy in premenopausal women. Alcohol Clin Exp Res 2005;29:1010-1017.
72. Hirani K, Khisti RT, Chopde CT. Behavioral action of ethanol in Porsolt's forced swim test: Modulation by 3α-hydroxy-5α-pregnan-20-one. Neuropharmacology 2002;43:1339-1350.
73. Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT. Evaluation of GABAergic neuroactive steroid 3α-hydroxy-5α-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology (Berl) 2005;180:267-278.
74. Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000;85:4650-4656.
75. Jain NS, Hirani K, Chopde CT. Reversal of caffeine-induced anxiety by neurosteroid 3α-hydroxy-5α-pregnane-20-one in rats. Neuropharmacology 2005;48:627-638.
76. Kaminski RM, Marini H, Kim WJ, Rogawski MA. Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia 2005;46:819-827.
77. Kaufman KD, Dawber RP. Finasteride, a Type 2 5α-reductase inhibitor, in the treatment of men with androgenetic alopecia. Exp Opin Invest Drugs 1999;8:403-15.
78. Kenny B, Ballard S, Blagg J, Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem 1997;40:1293-1315.
79. Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnane-20-one in mice forced swim test. Pharmacol Biochem Behav 2000;67:137-143.
80. Khisti RT, VanDoren MJ, Matthews DB, Morrow AL. Ethanol-induced elevation of 3α-hydroxy-5α-pregnane-20-one does not modulate motor incoordination in rats. Alcohol Clin Exp Res 2004;28:1249-1256.
81. Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: The prostate cancer prevention trial revisited. J Clin Oncol 2005;23:7460-7466.
82. Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999;288:679-684.
83. Kosobud A, Crabbe JC. Ethanol withdrawal in mice bred to be genetically prone or resistant to ethanol withdrawal seizures. J Pharmacol Exp Ther 1986;238:170-177.
84. Le Melledo JM, Baker G. Role of progesterone and other neuroactive steroids in anxiety disorders. Expert Rev Neurother 2004;4:851-860.
85. Lephart ED. Age-related changes in brain and pituitary 5α-reductase with finasteride (Proscar) treatment. Neurobiol Aging 1995;16:647-650.
86. Lephart ED, Ladle DR, Jacobson NA, Rhees RW. Inhibition of brain 5α-reductase in pregnant rats: Effects on enzymatic and behavioral activity. Brain Res 1996;739:356-360.
87. Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother 2004;5:933-940.
88. Logan YT, Belgeri MT. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia. Am J Geriatr Pharmacother 2005;3:103-114.
89. Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil Steril 2003;79:942-946.
90. A receptor. Mechanism of action and physiological significance. Prog Neurobiol 1992;38:379-395.
91. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51:677-686.
92. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505-508.
93. McEwen BS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991;12:141-147.
94. Mellon SH, Vaudry H. Biosynthesis of neurosteroids and regulation of their synthesis. Int Rev Neurobiol 2001;46:33-78.
95. Morrow AL, Janis GC, VanDoren MJ, et al. Neurosteroids mediate pharmacological effects of ethanol: A new mechanism of ethanol action? Alcohol Clin Exp Res 1999;23:1933-1940.
96. Moss ML, Kuzmic P, Stuart JD, et al. Inhibition of human steroid 5α reductases type I and II by 6-aza-steroids: Structural determinants of one-step vs two-step mechanism. Biochemistry 1996;35:3457-3464.
97. Muderris, II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000;73:984-987.
98. Neubauer BL, Gray HM, Hanke CW, et al. LY191704 inhibits type I steroid 5α-reductase in human scalp. J Clin Endocrinol Metab 1996;81:2055-2060.
99. Newmark ME, Penry JK, Catamenial epilepsy: A review. Epilepsia 1980;21:281-300.
100. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)- 3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991;16:15-21.
101. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005;52:301-311.
102. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-2322.
103. Peričić D, Svob D, Jazvinšćak M, Mirkovic K. Anticonvulsive effect of swim stress in mice. Pharmacol Biochem Behav 2000;66:879-886.
104. Pierucci-Lagha A, Covault J, Feinn R, et al. GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 2005;30:1193-1203.
105. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: A pilot study. Psychooncology 2002;11:518-23.
106. Purdy RH, Morrow AL, Moore PH, Jr., Paul SM. Stress-induced elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88:4553-4557.
107. Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol Sci 2003;24:103-106.
108. Reddy DS. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 2004;62:99-118.
109. Reddy DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol. Neuroscience 2004;129:195-207.
110. Reddy DS, Castaneda DC, O'Malley BW, Rogawski MA. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther 2004;310:230-239.
111. Reddy DS, O'Malley BW, Rogawski MA. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 2005;48:14-24.
112. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J Pharmacol Exp Ther 2000;294:909-915.
113. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001;42:337-344.
114. A receptor function and seizure susceptibility. J Neurosci 2002;22:3795-3805.
115. Rhodes ME, Frye CA. Attenuating 5α-pregnane-3α-ol-20-one formation in the hippocampus of female rats increases pentylenetetrazole-induced seizures. Epilepsy Behav 2005;6:140-146.
116. Rittmaster RS. 5α-reductase inhibitors. J Androl 1997;18:582-587.
117. Rittmaster RS, Stoner E, Thompson DL, Nance D, Lasseter KC. Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989;10:259-262.
118. Romeo E, Brancati A, De Lorenzo A, et al. Marked decrease of plasma neuroactive steroids during alcohol withdrawal. Clin Neuropharmacol 1996;19:366-369.
119. Romeo E, Pompili E, di Michele F, et al. Effects of fluoxetine, indomethacine and placebo on 3α,5-α-tetra-hydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J Biol Psychiatry 2000;1:101-104.
120. Romeo E, Strohle A, Spalletta G, et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;155:910-913.
121. Rosciszewska D, Buntner B, Guz I, Zawisza L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986;49:47-51.
122. Roy AK, Chatterjee B. Androgen action. Crit Rev Eukaryot Gene Exp 1995;5:157-76.
123. Rupprecht R, Holsboer F. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trend Neurosci 1999;22:410-416.
124. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2001;75:496-500.
125. A receptor activity in rat hippocampus. J Neurosci 2004;24:6521-6530.
126. Schanzer W. Metabolism of anabotic androgenic steroids. Clin Chem 1996;42:1001-1020.
127. Schule C, Romeo E, Uzunov DP, et al. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3α-hydroxysteroid dehydrogenase activity. Mol Psychiatry 2006;11:261-272.
128. Seyle H. The anesthetic effect of steroid hormones. Proc Soc Exp Biol Med 1941;46:116-121.
129. 44 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998;392:926-930.
130. 4 subunit in association with increased anxiety. J Neurosci 1998;18:5275-5284.
131. Smith SS, Ruderman Y, Frye C, Homanies G, Yuan M. Steroid withdrawal in the mouse results in anxiogenic effects of 3α,5β-THP: A possible model of premenstrual dysphoric disorder. Psychopharmacology (Berl) 2005:1-11.
132. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996;30:16-27.
133. Stoner E. The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 1990;37:375-378.
134. Strohle A, Romeo E, Hermann B, et al. Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999;45:274-277.
135. Stuart JD, Lee FW, Simpson Noel D, et al. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5α-reductases: Determinants for different in vivo activities of G1198745 and finasteride in the rat. Biochem Pharmacol 2001;62:933-942.
136. Sudduth SL, Koronkowski MJ. Finasteride: The first 5α-reductase inhibitor. Pharmacotherapy 1993;13:309-329.
137. Tartagni M, Schonauer MM, Cicinelli E, et al. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. Fertil Steril 2004;82:752-755.
138. Tennent BJ, Smith ER, Davidson JM. The effects of estrogen and progesterone on female rat proceptive behavior. Horm Behav 1980;14:65-75.
139. Thigpen AE, Russell DW. Four-amino acid segment in steroid 5α-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J Biol Chem 1992;267:8577-8583.
140. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993;92:903-910.
141. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
142. Titus MA, Gregory CW, Ford OH, 3rd, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-4371.
143. Torres JM, Ortega E. Alcohol intoxication increases allopregnanolone levels in female adolescent humans. Neuropsychopharmacology 2003;28:1207-1209.
144. Torres JM, Ortega E. Alcohol intoxication increases allopregnanolone levels in male adolescent humans. Psychopharmacology (Berl) 2004;172:352-355.
145. Townsend KA, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother 2004;38:1070-1073.
146. Trueb RM. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal women. Dermatology 2004;209:202-207.
147. Ugale RR, Mittal N, Hirani K, Chopde CT. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice. Brain Res 2004;1023:102-111.
148. Uzunova V, Sheline Y, Davis JM, et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:3239-3244.
149. van Luijtelaar G, Budziszewska B, Tetich M, Lason W. Finasteride inhibits the progesterone-induced spike-wave discharges in a genetic model of absence epilepsy. Pharmacol Biochem Behav 2003;75:889-894.
150. van Niekerk JK, Huppert FA, Herbert J. Salivary cortisol and DHEA: Association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology 2001;26:591-612.
151. VanDoren MJ, Matthews DB, Janis GC, Grobin AC, Devaud LL, Morrow AL. Neuroactive steroid 3α-hydroxy-5α-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. J Neurosci 2000;20:1982-1989.
152. Walf AA, Sumida K, Frye CA. Inhibiting 5α-reductase in the amygdala attenuates antianxiety and anti-depressive behavior of naturally receptive and hormone-primed ovariectomized rats. Psychopharmacology (Berl) 2005:1-10 [Oct 12, epub].
153. Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: Effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 1999;30:264-288.
154. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005;118:850-857.
155. Zimmerberg B, Brunelli SA, Fluty AJ, Frye CA. Differences in affective behaviors and hippocampal allopregnanolone levels in adult rats of lines selectively bred for infantile vocalizations. Behav Brain Res 2005;159:301-311.
156. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon®), Tamsulosin or Finasteride. Eur Urol 2005;48:269-276.